Adrenal Exhaustion Syndrome in Critically Ill Patients Without Improvement

Survival Clinical Trial

Official title:

Change of Serum Cortisol Levels in Patients Without Improvement in Intensive Care Unit

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00674284
• Other study ID #: 200802022R
• Status: Completed
• Phase: N/A
• First received: May 5, 2008
• Last updated: November 23, 2009
• Start date: February 2008
• Est. completion date: May 2008

Study information

• Verified date: November 2009
• Source: National Taiwan University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

We study the relationship between patient outcomes and sequential changes of serum cortisol level.

Description:

Elevated corticosteroid level to meet physiologic needs during acute illness is a protective response for stress. This homeostasis is maintained by the hypothalamic-pituitary-adrenal (HPA) axis. However, inadequate response as corticosteroid insufficiency in critically ill patients is reported with increasing frequency, especially in severe sepsis and septic shock. Thus, corticosteroids could be beneficial for septic shock or severe acute illness.

Once considered as normal adrenal function, adrenal insufficiency may developed later with chronic critical illness as adrenal exhaustion syndrome. It is easily overlooked and is possible due to the chronic secretion of systemic cytokines or other HPA axis-suppressive substances. There is still no consensus how often adrenal function testing should be repeated, although a re-evaluation should be considered if clinical symptoms and signs suggest adrenal insufficiency or deteriorating clinical condition.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: May 2008
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age over 18

• ICU admission

• had two cortisol data

Exclusion Criteria:

• first cortisol data abnormal

• cortisol data not checked in ICU

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Survival

Locations

Country	Name	City	State
Taiwan	Chao-Chi Ho	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan,